While Denali Therapeutics Inc has underperformed by -0.38%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DNLI rose by 38.77%, with highs and lows ranging from $33.33 to $14.56, whereas the simple moving average jumped by 0.70% in the last 200 days.
On January 07, 2025, Robert W. Baird started tracking Denali Therapeutics Inc (NASDAQ: DNLI) recommending Outperform. A report published by William Blair on January 03, 2025, Initiated its previous ‘Outperform’ rating for DNLI. Stifel also Upgraded DNLI shares as ‘Buy’, setting a target price of $37 on the company’s shares in a report dated December 16, 2024. Cantor Fitzgerald October 07, 2024d its ‘Overweight’ rating to ‘Neutral’ for DNLI, as published in its report on October 07, 2024. Citigroup’s report from December 13, 2023 suggests a price prediction of $32 for DNLI shares, giving the stock a ‘Buy’ rating. JP Morgan also rated the stock as ‘Overweight’.
Analysis of Denali Therapeutics Inc (DNLI)
Further, the quarter-over-quarter decrease in sales is -100.00%, showing a negative trend in the upcoming months.
One of the most important indicators of Denali Therapeutics Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -35.09% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 9.98, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and DNLI is recording 959.81K average volume. On a monthly basis, the volatility of the stock is set at 6.04%, whereas on a weekly basis, it is put at 4.68%, with a gain of 0.43% over the past seven days. Furthermore, long-term investors anticipate a median target price of $40.00, showing growth from the present price of $23.41, which can serve as yet another indication of whether DNLI is worth investing in or should be passed over.
How Do You Analyze Denali Therapeutics Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 13.43%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 88.55% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
DNLI shares are owned by institutional investors to the tune of 88.55% at present.
